Arvaya Healthcare Secures BSE Nod for Share Swap Issue

Arvaya Healthcare Limited has received in-principle approval from the BSE for the issuance of 3,871,854 equity shares at Rs 40 per share.
This preferential issue is structured as a share swap, with a face value of Rs 10 per share.

Reader Takeaway: Regulatory approval greenlights share swap; investors should monitor allotment timelines and compliance with trading restrictions.

What just happened

The Bombay Stock Exchange has granted in-principle approval for Arvaya Healthcare to proceed with its planned preferential issue of over 3.87 million shares. This approval, issued under Regulation 28(1) of the SEBI (LODR) Regulations, marks a critical regulatory milestone required before the company can finalize the share allotment process.

Why this matters

The share swap arrangement signals a strategic move for the company, potentially involving an acquisition or equity restructuring. By securing this approval, Arvaya Healthcare can now move toward the formal allotment of shares, expanding its equity base at a fixed price of Rs 40 per share.

Regulatory Compliance and Conditions

The BSE has imposed strict conditions on the company to ensure market integrity. Arvaya Healthcare is responsible for:

• Monitoring all trades executed by the proposed allottees in the company’s stock.
• Securing formal undertakings from allottees that they will not participate in intra-day trading or sell shares prior to the official allotment date.
  Failure to meet these conditions rests with the issuer and may jeopardize the listing of these new securities.

What to track next

The company must now complete the actual allotment process and submit a formal listing application to the exchange. This filing, accompanied by required documentation and fees, must be submitted within 20 days of the allotment date. Shareholders should watch for these subsequent disclosures to confirm the successful completion of the corporate action.